Also known as Aricept
Donepezil, marketed under the trade name Aricept by its developer Eisai and partner Pfizer, is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic use is in the palliative treatment of mild to moderate Alzheimer's disease. Common side effects include gastrointestinal upset. It has an oral bioavailability of 100% and easily crosses the blood–brain barrier. Because it has a half-life of about 70 hours, it can be taken once a day.Source: Wikipedia
Estimated Total Cost: $209.52 for an average of 28 days supply
Patients are most commonly prescribed donepezil to treat delirium, alzheimer disease, disturbance of memory, and dementia.